On August 19, 2025, researchers at Assenxio, a biotechnology firm based in Barcelona, Spain, published findings on a potential new treatment targeting parasitic worms in the human body. The study, conducted over 18 months with 120 participants across Spain and Portugal, tested a compound derived from natural plant extracts, focusing on its efficacy against common intestinal worms such as Ascaris lumbricoides and hookworms. Results showed a 78% reduction in worm burden after a single 10-day treatment cycle, with follow-up tests at 30 days indicating a sustained 65% decrease in egg counts per gram of feces. The trial involved 45 men and 75 women aged 18 to 65, with no serious adverse effects reported; mild gastrointestinal discomfort affected 12 participants, resolving within 48 hours. The compound, administered in 200 mg daily doses, targets worm metabolism, disrupting their ability to absorb nutrients, leading to their expulsion. Assenxio plans to expand the trial to 500 participants by December 2025, including sites in Sweden, where soil-transmitted helminths affect an estimated 150,000 people annually. The company has filed for patent approval and aims to collaborate with health organizations for mass distribution, with preliminary production capacity set at 50,000 doses per month by mid-2026. The research builds on earlier studies of plant-based anthelmintics, marking a step toward alternative treatments.
www.34news.online
www.34news.online
